In vivo laser light distribution in human prostatic carcinoma
- PMID: 8158797
- DOI: 10.1016/s0022-5347(17)35270-9
In vivo laser light distribution in human prostatic carcinoma
Abstract
The extent of laser light diffusion within prostatic tumor is of major importance in the treatment of localized prostatic cancer with photodynamic therapy (PDT). The penetration of 633 nm. wavelength red light was studied in eleven patients with suspected prostatic cancer using a novel method suitable for in situ measurements. Light delivery and detector fiber, placed interstitially within the gland, determined light attenuation at different interfiber separations. Of 11 patients, 10 had bilateral and 1 had single lobe studies. The mean +/- the standard error of the mean attenuation coefficients (sigma eff) for benign and malignant prostate tissue were 0.35 +/- 0.02 mm-1 and 0.36 +/- 0.02 mm-1, respectively, indicating similar optical densities (p = .58). Patients with bilateral lobe involvement showed little intraglandular variation in sigma eff (p = 0.23). However, there was interpatient variation (sigma eff = 0.28 to 0.48 mm-1) reflecting biological differences which, though therapeutically important, were not statistically significant (p = 0.057). This study showed that treatment requires individualization and predicted that 4 cylindrical diffusers are expected to destroy 25 ml. of prostatic tumor with PDT.
Similar articles
-
In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland.Photochem Photobiol. 1995 Nov;62(5):882-6. doi: 10.1111/j.1751-1097.1995.tb09151.x. Photochem Photobiol. 1995. PMID: 8570727
-
An interstitial light assembly for photodynamic therapy in prostatic carcinoma.BJU Int. 1999 Nov;84(7):821-6. doi: 10.1046/j.1464-410x.1999.00314.x. BJU Int. 1999. PMID: 10532979
-
Optimization of multifiber light delivery for the photodynamic therapy of localized prostate cancer.Photochem Photobiol. 1993 Oct;58(4):589-93. doi: 10.1111/j.1751-1097.1993.tb04937.x. Photochem Photobiol. 1993. PMID: 8248336
-
Laser dosimetry studies in the prostate.J Clin Laser Med Surg. 1998 Feb;16(1):9-12. doi: 10.1089/clm.1998.16.9. J Clin Laser Med Surg. 1998. PMID: 9728124 Review.
-
[Photodynamic therapy (PDT) for early cervical cancer].Gan To Kagaku Ryoho. 1996 Jan;23(1):47-56. Gan To Kagaku Ryoho. 1996. PMID: 8546469 Review. Japanese.
Cited by
-
Photodynamic therapy for prostate cancer--a review of current status and future promise.Nat Clin Pract Urol. 2009 Jan;6(1):18-30. doi: 10.1038/ncpuro1274. Nat Clin Pract Urol. 2009. PMID: 19132003 Review.
-
Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.Clin Cancer Res. 2008 Aug 1;14(15):4869-76. doi: 10.1158/1078-0432.CCR-08-0317. Clin Cancer Res. 2008. PMID: 18676760 Free PMC article. Clinical Trial.
-
Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.Photochem Photobiol. 2005 Jan-Feb;81(1):96-105. doi: 10.1562/2004-06-25-RA-216. Photochem Photobiol. 2005. PMID: 15535736 Free PMC article. Clinical Trial.
-
Codonopis bulleynana Forest ex Diels inhibits autophagy and induces apoptosis of colon cancer cells by activating the NF-κB signaling pathway.Int J Mol Med. 2018 Mar;41(3):1305-1314. doi: 10.3892/ijmm.2017.3337. Epub 2017 Dec 21. Int J Mol Med. 2018. PMID: 29286074 Free PMC article.
-
Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.Lasers Surg Med. 2005 Jun;36(5):390-7. doi: 10.1002/lsm.20177. Lasers Surg Med. 2005. PMID: 15856509 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical